Harminder Phull
427 posts




$NVO keeps hiring sales and marketing employees for Alzheimer’s. Lucan just started as commercial director for Alzheimer’s covering Europe and Canada. They surely are gearing up for a potential big launch. However we still don’t have the data from Evoke and Evoke+. And these two trials are HIGH risk. I still think they will just miss that p0.05. But I’m also hearing chatter about possible filing even though they miss. But have to be very small miss. Anyway I like that they invest in commercial activities even before they know what the data will be. IF positive, then this can be a new “obesity run”. NVO would exclusive have the GLP1 Alzheimer’s market for 4 years before $LLY potentially could get that label as well $VKTX




















